Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021

Index by author

December 01, 2009; Volume 76,Issue 12
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

B

  1. Bartholomew, John R.

    1. You have access
      An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

C

  1. Coco, Maria

    1. You have access
      Treating the renal patient who has a fracture: Opinion vs evidence
      Maria Coco, MD, MS
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 684-688; DOI: https://doi.org/10.3949/ccjm.76a.09075

      The patient with chronic renal disease who has a fracture remains a unique management challenge. Opinions on treatment abound, but without adequate evidence to back them up.

L

  1. Lazar, Lawrence D.

    1. You have access
      Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
      Lawrence D. Lazar, MD and A. Michael Lincoff, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 707-714; DOI: https://doi.org/10.3949/ccjm.76a.09116

      Prasugrel (Effient) is faster and more consistent in its effects, but patients at high bleeding risk should still receive clopidogrel (Plavix).

  2. Lincoff, A. Michael

    1. You have access
      Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk
      Lawrence D. Lazar, MD and A. Michael Lincoff, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 707-714; DOI: https://doi.org/10.3949/ccjm.76a.09116

      Prasugrel (Effient) is faster and more consistent in its effects, but patients at high bleeding risk should still receive clopidogrel (Plavix).

M

  1. Malki, Monzr Al

    1. You have access
      An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

  2. Mandell, Brian F.

    1. You have access
      Low bone density is not always bisphosphonate deficiency
      Brian F. Mandell, MD, PhD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 683; DOI: https://doi.org/10.3949/ccjm/76a.12001

      Low bone density is not a one-size-fits-all disorder. We need to carefully consider the diagnostic and therapeutic options before assuming that low bone density is osteoporosis.

  3. Messerli, Franz H.

    1. You have access
      Is an ACE inhibitor plus an ARB more effective than either drug alone?
      Franz H. Messerli, MD and Melana Yuzefpolskaya, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 693-696; DOI: https://doi.org/10.3949/ccjm.76a.09052

      No. Dual renin-angiotensin system blockade has never been shown to reduce the rates of morbidity or death from any cause.

  4. Miller, Paul D.

    1. You have access
      Fragility fractures in chronic kidney disease: An opinion-based approach
      Paul D. Miller, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 715-723; DOI: https://doi.org/10.3949/ccjm.76a.08108

      When a patient with chronic kidney disease suffers a fragility fracture, a key question is whether the patient has osteoporosis or, instead, renal osteodystrophy. Bone densitometry does not help in this distinction.

O

  1. Osinbowale, Olusegun

    1. You have access
      An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

P

  1. Parsi, Mansour A.

    1. Acute pancreatitis: Problems in adherence to guidelines
      You have access
      Acute pancreatitis: Problems in adherence to guidelines
      Tyler Stevens, MD, Mansour A. Parsi, MD and R. Matthew Walsh, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 697-704; DOI: https://doi.org/10.3949/ccjm.76a.09060

      Evidence-based guidelines on managing acute pancreatitis are available, but many physicians are not following them.

S

  1. Schade, Andrew

    1. You have access
      An algorithm for managing warfarin resistance
      Olusegun Osinbowale, MD, MBA, RPVI, Monzr Al Malki, MD, Andrew Schade, MD, PhD and John R. Bartholomew, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 724-730; DOI: https://doi.org/10.3949/ccjm.76a.09062

      Some patients need higher-than-expected doses of warfarin to reach their target INR. The cause can be acquired (poor compliance, drug interactions) or hereditary.

  2. Stevens, Tyler

    1. Acute pancreatitis: Problems in adherence to guidelines
      You have access
      Acute pancreatitis: Problems in adherence to guidelines
      Tyler Stevens, MD, Mansour A. Parsi, MD and R. Matthew Walsh, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 697-704; DOI: https://doi.org/10.3949/ccjm.76a.09060

      Evidence-based guidelines on managing acute pancreatitis are available, but many physicians are not following them.

W

  1. Walsh, R. Matthew

    1. Acute pancreatitis: Problems in adherence to guidelines
      You have access
      Acute pancreatitis: Problems in adherence to guidelines
      Tyler Stevens, MD, Mansour A. Parsi, MD and R. Matthew Walsh, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 697-704; DOI: https://doi.org/10.3949/ccjm.76a.09060

      Evidence-based guidelines on managing acute pancreatitis are available, but many physicians are not following them.

Y

  1. Yuzefpolskaya, Melana

    1. You have access
      Is an ACE inhibitor plus an ARB more effective than either drug alone?
      Franz H. Messerli, MD and Melana Yuzefpolskaya, MD
      Cleveland Clinic Journal of Medicine December 2009, 76 (12) 693-696; DOI: https://doi.org/10.3949/ccjm.76a.09052

      No. Dual renin-angiotensin system blockade has never been shown to reduce the rates of morbidity or death from any cause.

Back to top
PreviousNext

In this issue

Cleveland Clinic Journal of Medicine: 76 (12)
Cleveland Clinic Journal of Medicine
Vol. 76, Issue 12
1 Dec 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Sign up for alerts
  • Editor's Picks
  • Most Cited
  • Most Read
Loading
Oral leukoplakia and oral cancer
A 50-year-old man presents with shortness of breath
Myasthenia gravis: Frequently asked questions
Central vision loss in a 44-year-old woman
Median rhomboid glossitis caused by tongue-brushing
Making best use of bone turnover markers to monitor oral bisphosphonate therapy
Asymptomatic granules on the buccal mucosa
Does my patient need to be screened or treated for a urinary tract infection?
Ignore e-cigarettes at your patient’s peril
Spontaneous oral hematoma diagnosed as angina bullosa hemorrhagica
Hypophosphatemia in a patient with an eating disorder
Scaly plaques in a malnourished patient
Confusion in a 22-year-old woman, and diagnostic uncertainty
How do we maximize diuresis in acute decompensated heart failure?

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire